Roche Drops Aleglitazar In Another Cardiology/Metabolics Setback
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Development of dual PPAR agonist aleglitazar terminated due to fractures, renal impairment and heart failure reported in the AleCardio study, leaving another hole in Roche’s cardiovascular/metabolic pipeline.